ST人福HW221043片临床试验获批准

Core Viewpoint - ST Renfu (600079) announced the approval of its drug HW221043 for clinical trials, marking a significant step in its development of a new treatment for advanced solid tumors [1] Group 1: Company Developments - ST Renfu's wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., received the clinical trial approval notice from the National Medical Products Administration for HW221043 [1] - HW221043 is a new molecular entity developed independently by the company, with no similar drugs approved for market in China or abroad [1] - The total research and development investment for HW221043 has reached approximately 24 million yuan [1]